186 related articles for article (PubMed ID: 10792270)
1. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
Di Bona E; Avvisati G; Castaman G; Luce Vegna M; De Sanctis V; Rodeghiero F; Mandelli F
Br J Haematol; 2000 Mar; 108(4):689-95. PubMed ID: 10792270
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Escudier SM; Kantarjian HM; Estey EH
Leuk Lymphoma; 1996 Feb; 20(5-6):435-9. PubMed ID: 8833399
[TBL] [Abstract][Full Text] [Related]
3. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
[TBL] [Abstract][Full Text] [Related]
4. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
[TBL] [Abstract][Full Text] [Related]
5. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
6. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
8. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.
Testi AM; Biondi A; Lo Coco F; Moleti ML; Giona F; Vignetti M; Menna G; Locatelli F; Pession A; Barisone E; De Rossi G; Diverio D; Micalizzi C; Aricò M; Basso G; Foa R; Mandelli F
Blood; 2005 Jul; 106(2):447-53. PubMed ID: 15677559
[TBL] [Abstract][Full Text] [Related]
9. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
Latagliata R; Breccia M; Fazi P; Vignetti M; Di Raimondo F; Sborgia M; Vincelli D; Candoni A; Salvi F; Rupoli S; Martinelli G; Kropp MG; Tonso A; Venditti A; Melillo L; Cimino G; Petti MC; Avvisati G; Lo-Coco F; Mandelli F;
Br J Haematol; 2011 Sep; 154(5):564-8. PubMed ID: 21751984
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
Koh LP; Goh YT; Teoh G; Tan P
Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
Avvisati G; Petti MC; Lo-Coco F; Vegna ML; Amadori S; Baccarani M; Cantore N; Di Bona E; Ferrara F; Fioritoni G; Gallo E; Invernizzi R; Lazzarino M; Liso V; Mariani G; Ricciuti F; Selleri C; Sica S; Veneri D; Mandelli F;
Blood; 2002 Nov; 100(9):3141-6. PubMed ID: 12384411
[TBL] [Abstract][Full Text] [Related]
12. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
Eardley AM; Heller G; Warrell RP
Leukemia; 1994 Jun; 8(6):934-9. PubMed ID: 8207987
[TBL] [Abstract][Full Text] [Related]
13. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
[TBL] [Abstract][Full Text] [Related]
14. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
[TBL] [Abstract][Full Text] [Related]
15. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
de la Serna J; Montesinos P; Vellenga E; Rayón C; Parody R; León A; Esteve J; Bergua JM; Milone G; Debén G; Rivas C; González M; Tormo M; Díaz-Mediavilla J; González JD; Negri S; Amutio E; Brunet S; Lowenberg B; Sanz MA
Blood; 2008 Apr; 111(7):3395-402. PubMed ID: 18195095
[TBL] [Abstract][Full Text] [Related]
16. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto.
Specchia G; Lo Coco F; Vignetti M; Avvisati G; Fazi P; Albano F; Di Raimondo F; Martino B; Ferrara F; Selleri C; Liso V; Mandelli F
J Clin Oncol; 2001 Oct; 19(20):4023-8. PubMed ID: 11600603
[TBL] [Abstract][Full Text] [Related]
17. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of Idarubicin-Based Stratified Therapy for Acute Promyelocytic Leukemia].
Guan W; Li WJ; Yang L; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):353-357. PubMed ID: 28446274
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.
Jeddi R; Kacem K; Ben Neji H; Mnif S; Gouider E; Aissaoui L; Ben Amor R; Ben Lakhal R; Ben Abid H; Belhadjali Z; Meddeb B
Hematology; 2008 Jun; 13(3):142-6. PubMed ID: 18702871
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
